Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.96
- Piotroski Score 2.00
- Grade Neutral
- Symbol (KNTE)
- Company Kinnate Biopharma Inc.
- Price $2.65
- Changes Percentage (-0.38%)
- Change -$0.01
- Day Low $2.64
- Day High $2.68
- Year High $7.19
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $30.00
- High Stock Price Target $30.00
- Low Stock Price Target $30.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.78
- Trailing P/E Ratio -0.95323741007194
- Forward P/E Ratio -0.95323741007194
- P/E Growth -0.95323741007194
- Net Income $-112,649,000